Intravenous Immunoglobulin (IVIG) Therapy for COVID-19 Omicron (B.1.1.529) Variant with Acute Respiratory Distress Syndrome

Dewi Arum Sawitri, Arie Zainul Fatoni

Abstract


Background: COVID-19 become the pandemic and infect more than million people. The World health organization and other clinical institutions have not yet established a definitive therapy to treat this disease due to a rapid virus mutation and anomaly.

Case: A 78-year-old man who had previously confirmed COVID-19 was referred to the COVID-19 intensive care unit (ICU), the patient had geriatrics comorbid, cerebrovascular accident (CVA) infarction, and hypertension. The patient came with unresponsive awareness, and complaints of right hemiparesis and dysarthria. Other symptoms included cough, shortness of breath, and fever. Shortness of breath aggravates, blood pressure increases, and SpO2 was 86%. We decide intubated the patient because have a sign of respiratory distress. Patients receive standard therapy for COVID-19. On the second day, patient receive intravenous immunoglobulin (IVIG) gamaras 20 g. IVIG therapy perform for five days. On the fifth day of treatment in the ICU, the patient’s complaints had decreased and the patient breathed spontaneously with high flow nasal cannula (HFNC).

Conclusion: Intravenous immunoglobulin (IVIG) therapy on the COVID-19 Omicron variant patient with ARDS produce a positive outcome. Patients treat with IVIG for 5 days show an improvement in breathing, laboratory result and chest x-ray. 


Keywords


acute respiratory distress syndrome; COVID-19; IVIG;

Full Text:

PDF

References


BMJ Best Practice. Coronavirus disease 2019 (COVID-19). BMJ Best Practice 2020. Available from https://doi.org/bestpractice.bmj.com/topics/en-gb/3000168.

Kominfo RI. Tujuh hal yang perlu diketahui dari varian Omicron penyebab COVID-19 [poster]. Jakarta: Kominfo RI; 2021. Available from: https://covid19.go.id/edukasi/ masyarakat-umum/7-hal-yang-perlu-diketahui- dari-varian-omicron-penyebab-covid-19

Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistent to existing vaccines, scientists fear. BMJ. 2021; 375;n2943. doi: 10.1136/bmj.n2943

WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern [Internet]. WHO; 2021. Available from: https://www.who.int/news/item/26-11-2021- classification-of-omicron-(b.1.1.529)-sars-cov-2- variant-of-concern

Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2021;90:107205. doi:10.1016/j.intimp.2020.107205

Mazeraud A, Jamme M, Mancusi RL, dkk. Imunoglobulin intravena pada pasien dengan sindrom gangguan pernapasan akut (ICAR) sedang hingga parah terkait COVID-19: uji coba fase 3 multisenter, double-blind, terkontrol plasebo. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(21)00440 9.

Cao W, Liu X, Bai T, et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102. doi:10.1093/ofid/ofaa102

Tzilas V, Manali E, Papiris S, Bouros D. Intravenous immunoglobulin for the treatment of COVID-19 : a promising tool. Respiration. 2020; 99:1087–1089.

Guell E, Martín-Fernandez M, De la Torre M, et al. Impact of lymphocyte and neutrophil counts on mortality risk in severe communityacquired pneumonia with or without septic shock. J Clin Med. 2019; 8: 754.

Xiang HR, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. Int Immunopharmacol. 2021;96:107732. doi: 10.1016/j.intimp.2021.107732.

Flores-Oria CA, Saturno E, Ramanathan S, et al. Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review. SAGE Open Med Case Rep. 2021;9:2050313X211029699. doi:10.1177/2050313X211029699

Kolahchi, Z., Sohrabi, H., Ekrami Nasab, S. et al. Potential therapeutic approach of intravenous immunoglobulin against COVID-19. Allergy Asthma Clin Immunol. 2021;17: 105. https://doi.org/10.1186/s13223-021-00609-3

Li, Taisheng. The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia. Clinical Trial. 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04261426#contactlocation

Burhan E, Susanto AD, Nasution SA, et al. PEDOMAN TATALAKSANA COVID-19 Edisi ke-4. Jakarta: Kementerian Kesehatan. 2022: 46

Aggarwal A, Stella AO, Walker G, et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv; 2021.doi: 10.1101/2021.12.14.21267772.

Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600(7887):21. doi:10.1038/d41586-021-03552-w

Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022;62(2):412-422. doi:10.1021/acs.jcim.1c01451

Santoso, S. AZ Fatoni. Management of respiratory failure in patients with COVID-19 and multiple myeloma. Journal of Anaesthesia and Pain. 2022:3(3):51-53. doi: 10.21776/ub.jap.2022.003.03.03




DOI: http://dx.doi.org/10.21776/ub.jap.2023.004.01.04

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.